08:19 AM EST, 12/17/2025 (MT Newswires) -- Compugen ( CGEN ) said Wednesday it has amended its exclusive license agreement with AstraZeneca ( AZN ) to monetize a portion of its rilvegostomig future royalties.

Compugen ( CGEN ) said it will receive an upfront payment of $65 million and a potential additional $25 million upon the next milestone payment on acceptance of a biologics license application, for a portion of its existing royalty interest in rilvegostomig.

The transaction is expected to extend Compugen's ( CGEN ) cash runway into 2029, the company said.

AstraZeneca ( AZN ) is advancing rilvegostomig, a first-in-class dual-checkpoint bispecific, in a broad development program, including 11 ongoing phase 3 trials in patients with lung, gastrointestinal, and endometrial cancers, Compugen ( CGEN ) said.

Compugen ( CGEN ) shares were more than 14% higher in premarket trading.